Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-07-25, Stock:LLY, The news for the past five days is as follows:
2018-07-18: NEWS1: Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon.NEWS2: Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon.NEWS3: Estimates and Recommendations for Eli Lilly on July 18.NEWS4: Pfizer, Eli Lilly non-opioid pain drug nears finish line.NEWS5: Eli Lilly’s Q2 2018 Estimates: Expect Revenue Growth.NEWS6: Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon.NEWS7: What to Expect from Eli Lilly and Company’s Q2 2018 Earnings.NEWS8: Pfizer-Lilly pain drug meets late-stage trial goals.NEWS9: Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain.NEWS10: Pfizer And Lilly Announce Positive Results From Phase 3 Trial Of Tanezumab.NEWS11: Pfizer And Lilly Announce Positive Results From Phase 3 Trial Of Tanezumab.
2018-07-19: NEWS1: Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE).NEWS2: Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?.NEWS3: Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?.NEWS4: Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study.NEWS5: Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study.NEWS6: LLY vs. NVO: Which Stock Is the Better Value Option?.NEWS7: LLY vs. NVO: Which Stock Is the Better Value Option?.NEWS8: Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?.NEWS9: Pfizer & Lilly&apos;s Pain Candidate Succeeds in Phase III Study.NEWS10: The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon.NEWS11: The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon.NEWS12: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS13: Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint.NEWS14: The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon.NEWS15: Lilly's Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease.NEWS16: Lilly: Tradjenta's CARMELINA Cardiovascular Outcome Trial Meets Primary Endpoint.NEWS17: Lilly: Tradjenta's CARMELINA Cardiovascular Outcome Trial Meets Primary Endpoint.
2018-07-20: NEWS1: Johnson & Johnson’s Revenues Came in ahead of Estimates in Q2.NEWS2: Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label.NEWS3: Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label.NEWS4: Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label.NEWS5: Better Buy: Eli Lilly and Company vs. Merck & Co..NEWS6: Better Buy: Eli Lilly and Company vs. Merck & Co..NEWS7: Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals.NEWS8: Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals.NEWS9: Highlights from Lilly's Alzheimer's Disease Pipeline at the Alzheimer's Association International Conference® 2018 (AAIC® 2018).NEWS10: Eli Lilly Scores a Win in Diabetes.NEWS11: Eli Lilly Scores a Win in Diabetes.NEWS12: Pharma Stock Roundup: JNJ & NVS&apos; Q2 Earnings, FDA Approvals.NEWS13: Better Buy: Eli Lilly and Company vs. Merck & Co..NEWS14: Eli Lilly Scores a Win in Diabetes.
2018-07-23: NEWS1: Pre-Market Earnings Report for July 24, 2018 :  VZ, MMM, UTX, LLY, LMT, BIIB, SHW, KMB, CNC, IQV, PCAR, AGR.NEWS2: Pre-Market Earnings Report for July 24, 2018 :  VZ, MMM, UTX, LLY, LMT, BIIB, SHW, KMB, CNC, IQV, PCAR, AGR.NEWS3: Eli Lilly's Q2 Earnings Preview.NEWS4: Major Averages Close Mixed Following Lackluster Session - U.S. Commentary.NEWS5: Major Averages Close Mixed Following Lackluster Session - U.S. Commentary.NEWS6: BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions.NEWS7: BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions.NEWS8: Novartis in Q2 2018: Segment Performances.NEWS9: Biogen: Analysts’ Views before Its Second-Quarter Results.
2018-07-24: NEWS1: Asian Markets Exhibit Mixed Trend.NEWS2: Asian Markets Exhibit Mixed Trend.NEWS3: Renewed Support Predicted For Thai Stock Market.NEWS4: Renewed Support Predicted For Thai Stock Market.NEWS5: Japanese Market Rises.NEWS6: Japanese Market Rises.NEWS7: Indonesia Bourse May Add To Its Winnings.NEWS8: Indonesia Bourse May Add To Its Winnings.NEWS9: Australian Market Drifts Lower.NEWS10: Australian Market Drifts Lower.NEWS11: Win Streak May Continue For Hong Kong Shares.NEWS12: Win Streak May Continue For Hong Kong Shares.NEWS13: Edited Transcript of LLY earnings conference call or presentation 24-Jul-18 1:00pm GMT.NEWS14: China Stocks Draw Positive Lead For Wednesday.NEWS15: China Stocks Draw Positive Lead For Wednesday.NEWS16: S&P reaches highest level since February as Alphabet shares soar.NEWS17: Taiwan Bourse May Crack Resistance At 11,000 Points.NEWS18: Taiwan Bourse May Crack Resistance At 11,000 Points.NEWS19: Health Care Sector Update for 07/24/2018: BMY,BIIB,IMRN,LLY.NEWS20: Health Care Sector Update for 07/24/2018: BMY,BIIB,IMRN,LLY.NEWS21: Singapore Bourse May Find Traction On Wednesday.NEWS22: Singapore Bourse May Find Traction On Wednesday.NEWS23: Malaysia Shares May See Continued Support.NEWS24: Malaysia Shares May See Continued Support.NEWS25: Mild Upside Seen For South Korea Stock Market.NEWS26: Mild Upside Seen For South Korea Stock Market.NEWS27: Health Care Sector Update for 07/24/2018: BIIB,IMRN,LLY.NEWS28: Health Care Sector Update for 07/24/2018: BIIB,IMRN,LLY.NEWS29: AstraZeneca Sells Atacand's European Rights to Cheplapharm.NEWS30: AstraZeneca Sells Atacand's European Rights to Cheplapharm.NEWS31: Lilly (LLY) Tops Q2 Earnings, Chooses IPO Path for Elanco.NEWS32: Lilly (LLY) Tops Q2 Earnings, Chooses IPO Path for Elanco.NEWS33: Lilly plans Elanco IPO, posts quarterly profit above estimates.NEWS34: Eli Lilly's Good Quarter Masks Deeper Risks.NEWS35: Eli Lilly (LLY) Tops Q2 Earnings and Revenue Estimates.NEWS36: Eli Lilly (LLY) Tops Q2 Earnings and Revenue Estimates.NEWS37: AstraZeneca Sells Atacand&apos;s European Rights to Cheplapharm.NEWS38: Biogen, Eli Lilly earnings beats push industry stocks up.NEWS39: Stocks - Alphabet, Harley-Davidson, Verizon Gain in Pre-market; Whirlpool Tanks.NEWS40: Eli Lilly and Company -- Moody's: Lilly's planned separation of Elanco is credit negative.NEWS41: Lilly (LLY) Tops Q2 Earnings, Chooses IPO Path for Elanco.NEWS42: Johnson & Johnson Updated Fiscal 2018 Guidance.NEWS43: How Eli Lilly’s Segments Performed in Q2 2018.NEWS44: Biotech ETFs surge, supported by strong results from Biogen and Eli Lilly.NEWS45: Eli Lilly (LLY) Tops Q2 Earnings and Revenue Estimates.NEWS46: Alphabet Isn't the Only Company With an Earnings Blowout - Here's the Rundown.NEWS47: Drugmaker Lilly plans IPO for part of animal health business.NEWS48: Corrected: Eli Lilly to take animal health unit public, profit beats estimates.NEWS49: Stocks to Watch: Alphabet, Verizon, Whirlpool, Harley-Davidson, 3M, Lockheed Martin, Eli Lilly.NEWS50: Benzinga Pro's 5 Stocks To Watch Today.NEWS51: Eli Lilly (LLY) Tops Q2 Earnings & Sales, Ups 2018 View.NEWS52: Eli Lilly (LLY) Tops Q2 Earnings & Sales, Ups 2018 View.NEWS53: Eli Lilly Shares Climb on Earnings Beat.NEWS54: Eli Lilly Surpasses Estimates, Reports Growth in Q2 2018.NEWS55: Eli Lilly Plans to Separate Elanco through Potential IPO.NEWS56: Eli Lilly to take animal health unit public.NEWS57: Eli Lilly Won't Raise Drug Prices This Year, CEO Says.NEWS58: Eli Lilly Won't Raise Drug Prices This Year, CEO Says.NEWS59: Stocks Remain Mostly Positive In Mid-Day Trading - U.S. Commentary.NEWS60: Stocks Remain Mostly Positive In Mid-Day Trading - U.S. Commentary.NEWS61: Eli Lilly (LLY) Tops Q2 Earnings & Sales, Ups 2018 View.NEWS62: Stocks making the biggest moves premarket: MMM, UTX, VZ, LLY & more.NEWS63: Analysts’ Targets and Recommendations for Amgen Stock.NEWS64: Eli Lilly tops 2Q earnings, guidance expectations.NEWS65: [$$] Eli Lilly plans listing of animal health unit.NEWS66: Eli Lilly CEO: We're growing based on the back of our new....NEWS67: Eli Lilly spins off animal health unit, second quarter beats.NEWS68: Eli Lilly shares rise after animal health IPO, earnings beat.NEWS69: Eli Lilly shares surge after animal health IPO, earnings beat.NEWS70: Eli Lilly&apos;s stock jumps after earnings beat, potential IPO of Elanco Animal Health.NEWS71: Earnings Reaction History: Eli Lilly & Co., 36.4% Follow-Through Indicator, 2.2% Sensitive.NEWS72: Earnings Reaction History: Eli Lilly & Co., 36.4% Follow-Through Indicator, 2.2% Sensitive.NEWS73: Stocks Move Notably Higher On Upbeat Earnings News - U.S. Commentary.NEWS74: Stocks Move Notably Higher On Upbeat Earnings News - U.S. Commentary.NEWS75: Eli Lilly to take animal health unit public.NEWS76: Lilly Opts for Animal-Drugs Spinoff Instead of Selling Unit.NEWS77: Lilly Delivers Strong Second-Quarter 2018 Results, Revises EPS Guidance.NEWS78: Eli Lilly plans initial public offering of its Elanco animal health unit.NEWS79: Lilly to Separate Elanco Animal Health with Initial Public Offering.NEWS80: Dow is set to rise nearly 150 points following strong earnings from Google parent Alphabet.NEWS81: Dow futures are set to rise following strong earnings from Google parent Alphabet.NEWS82: US futures tick higher as earnings season picks up.NEWS83: Stocks May Move To The Upside In Early Trading - U.S. Commentary.NEWS84: Stocks May Move To The Upside In Early Trading - U.S. Commentary.NEWS85: Eli Lilly Q2 18 Earnings Conference Call At 9:00 AM ET.NEWS86: Eli Lilly Q2 18 Earnings Conference Call At 9:00 AM ET.NEWS87: Eli Lilly Revises Guidance; To Pursue IPO Of Elanco - Quick Facts.NEWS88: Eli Lilly Revises Guidance; To Pursue IPO Of Elanco - Quick Facts.NEWS89: Eli Lilly And Co. Q2 18 Earnings Conference Call At 9:00 AM ET.NEWS90: Eli Lilly And Co. Q2 18 Earnings Conference Call At 9:00 AM ET.

Answer: Rise